21 Mar 2018 07:00
21 March 2018
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Resignation of Director
Venn Life Sciences ("Venn") an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations announces that Jonathan Hartshorn is to step down from his position as Finance Director of the Company with immediate effect.
Tony Richardson said "Jonathan is moving on to pursue other opportunities. I would like to thank him for his contribution and wish him well in his future endeavours". The Company will in due course announce a permanent replacement but, in the meantime, the finance function will report directly to the Chief Executive Officer.
Enquiries:
Venn Life Sciences Holdings Plc | ||
Allan Wood, Non-Executive Chairman | ||
Tony Richardson, Chief Executive Officer | Tel: +353 1 5499341 | |
Cenkos (Nominated Advisor and Joint Broker) Mark Connelly/Steve Cox (Corporate Finance) | Tel: +44(0)20 3764 2341 | |
Davy (ESM Adviser and Joint Broker) | ||
Fergal Meegan / Matthew de Vere White (Corporate Finance) | Tel: +353 1 679 6363 | |
Hybridan LLP (Joint Broker) | Tel: +44 (0)20 3764 2341 | |
Claire Louise Noyce | ||
About Venn Life Sciences: Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.
Further information in relation to Venn Life Sciences www.vennlifesciences.com